Lv1
60 积分 2025-06-01 加入
Neoadjuvant radio-chemoimmunotherapy versus neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer: A pooled analysis of prospective studies
4个月前
已关闭
Neoadjuvant hypofractionated radiotherapy plus tislelizumab with anlotinib followed by adjuvant tislelizumab with anlotinib in patients with resectable non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial (NEO-PIONEER)
4个月前
已关闭
皖公网安备34019202002308
